Clinical Trial

Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N

Study acronym: TATIANA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main objective of this research is to increase the life expectancy of patients with advanced mouth and throat cancer, by adding avelumab to the standard TPEx treatment. All participants in this research will receive the same treatment which will take place in two phases: * 1st phase chemotherapy + immunotherapy: standard reference treatment (Docetaxel + cisplatin or carboplatin + cetuximab) * 2nd phase immunotherapy: cetuximab combined with avelumab which is the treatment under study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-11.
Status change: Not Yet Recruiting → Recruiting 2025-01-14
Trial Details
NCT Number NCT06640725
Lead Sponsor Groupe Oncologie Radiotherapie Tete et Cou
Conditions Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Enrollment 70 participants
Start Date 2025-01-02
Primary Completion 2027-10-02 (estimated)
Study Completion 2028-12-02 (estimated)
Updated on ClinicalTrials.gov 2025-01-15